Stay Informed on Corporate Sustainability

Author: Archie Villaflores

Strategic partnerships that unlock AI-driven discovery and acquisitions that consolidate cell therapy manufacturing drive pharmaceutical sector growth. Companies securing investment whilst acquiring clinical-stage assets demonstrate how capital deployment accelerates therapeutic development and market entry. Turning the clock back to last year's accomplishments, 'Uniphar Medtech wins Corporate Social Responsibility Programme of the Year at Pharma Industry Awards 2025' earned recognition for its Local Competitive Advantage initiative transforming local inclusion into a talent pipeline. This achievement establishes benchmarks for the 2026 awards, where strategic social investment aligned with business objectives will distinguish CSR leadership. Furthermore, 'Belfast drug discovery firm secures South Korean strategic investment' demonstrates how AI-enabled platforms attract international biotech backing through multi-omic data mining and oncology programme validation. AMPLY Discovery's partnership with Keeps Biomed strengthens Northern Ireland's pharmaceutical research capabilities whilst exploring collaboration opportunities. Meanwhile, 'Gilead Sciences acquires CAR-T specialist Arcellx for $7.8 billion' reflects how pharmaceutical majors consolidate cell therapy manufacturing through strategic acquisition of companies approaching regulatory approval. The transaction adds anito-cel to Gilead's blood cancer portfolio with FDA action anticipated by December 2026. Investment and acquisition define pharmaceutical sector momentum. Read each story to understand how strategic partnerships and manufacturing consolidation are accelerating therapeutic development.

Author: Jed Nykolle Harme

Honoured for transformative community impact in 2025, Uniphar Medtech won Corporate Social Responsibility Programme of the Year at the Pharma Industry Awards 2025, setting a benchmark for talent development as the sector looks toward 2026.

Author: Archie Villaflores

United States pharmaceutical manufacturer AbbVie will invest $380 million (€322 million) to construct two manufacturing facilities at its North Chicago campus. The plants will produce active pharmaceutical ingredients for obesity and neuroscience medications, creating 300 positions.

Author: Archie Villaflores

United States-based pharmaceutical company Gilead Sciences has agreed to acquire CAR-T specialist Arcellx for $7.8 billion (€6.6 billion). The acquisition strengthens Gilead's manufacturing excellence capabilities in cell therapy production for blood cancer treatment.

Author: Archie Villaflores

Australia's Argent BioPharma has delivered its largest commercial shipment of CannEpil to Ireland, where the epilepsy treatment is fully reimbursed under National Health Insurance. The €467,000 shipment strengthens Ireland's pharmaceutical supply chain capabilities for neurological therapies.

Author: Archie Villaflores

DHL Group is expanding its dedicated airfreight cold chain network to Ireland and seven other countries to meet pharmaceutical transport demand. The €2 billion investment strengthens temperature-controlled logistics capabilities for biologics and cell and gene therapies.

Author: Archie Villaflores

Belfast-based drug discovery company AMPLY Discovery has secured strategic investment from South Korean biotech firm Keeps Biomed. The partnership strengthens Northern Ireland's pharmaceutical manufacturing excellence capabilities and advances AI-driven oncology drug development.

Author: Archie Villaflores

Pharmaceutical sector growth is shaped by strategic acquisitions and research partnerships that extend commercial portfolios whilst strengthening supply chain resilience. Narcolepsy treatment consolidation, award recognition documentation, and medicinal plant collaboration converge to demonstrate sector dynamism. First, 'Pharma Industry Awards 2025 Book of the Night captures a defining evening for Irish pharma' preserves achievement narratives including AbbVie Ireland's dual category wins and Deciphex's AI-powered innovation recognition. This commemorative publication establishes benchmarks as the sector advances toward the upcoming 2026 awards. Additionally, 'Alkermes completes $2.3 billion acquisition of Avadel Pharmaceuticals' demonstrates how Irish biopharmaceutical companies consolidate commercial portfolios through cash-and-debt transactions adding FDA-approved narcolepsy treatments. Strategic acquisitions accelerate market entry whilst leveraging estimated populations of oxybate-eligible patients across significant growth opportunities. Meanwhile, 'BauerTek partners with Rizal Technological University on medicinal plant production' reflects how pharmaceutical manufacturers establish academic cultivation partnerships to secure traceable raw materials for supplement operations. Research collaboration optimises growing conditions and extraction processes whilst supporting knowledge transfer between industry and academia. These stories frame a sector where acquisition strategy, achievement documentation, and supply chain innovation determine competitive advantage. Explore each article to understand how acquisitions and partnerships are advancing pharmaceutical sector positioning.

Author: Jed Nykolle Harme

The official post-event publication from Ireland's prestigious Pharma Industry Awards 2025 recognition programme is now available to read.

Author: Archie Villaflores

Ireland-based biotech company Aerska has raised $39 million in Series A funding to advance brain shuttle technology for delivering RNA medicines across the blood-brain barrier for neurological diseases.